| scholarly article | Q13442814 |
| P50 | author | David T Felson | Q37393431 |
| P2093 | author name string | Bogardus ST | |
| Concato J | |||
| Fraenkel L | |||
| Wittink DR | |||
| P2860 | cites work | Explaining risks: turning numerical data into meaningful pictures | Q30685742 |
| Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review | Q40645943 | ||
| Radiographic outcome after three years of patients with early erosive rheumatoid arthritis treated with intramuscular methotrexate or parenteral gold. Extension of a one-year double-blind study in 174 patients | Q43911382 | ||
| Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials | Q44117657 | ||
| A toxicity index for comparison of side effects among different drugs | Q45009872 | ||
| Measuring health status in arthritis. The arthritis impact measurement scales. | Q51270176 | ||
| Bridging the gap between doctors' and patients' expectations of asthma management. | Q51671986 | ||
| What do patients and rheumatologists regard as an 'acceptable' risk in the treatment of rheumatic disease? | Q52875665 | ||
| Incorporating patients' preferences into medical decisions | Q72476898 | ||
| Risk communication in rheumatoid arthritis | Q73064666 | ||
| Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group | Q73207664 | ||
| A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis | Q73235899 | ||
| Safety, efficacy, and mortality in a long-term cohort of patients with rheumatoid arthritis taking methotrexate: followup after a mean of 13.3 years | Q73343824 | ||
| Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)–Fc Fusion Protein | Q73502940 | ||
| Lack of congruence in the ratings of patients' health status by patients and their physicians | Q73778701 | ||
| Preference for disclosure of information among patients with rheumatoid arthritis | Q73810979 | ||
| Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes | Q74455180 | ||
| The risk of treatment. A study of rheumatoid arthritis patients' attitudes | Q74628502 | ||
| Methodological issues in the application of conjoint analysis in health care | Q74820029 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| rheumatoid arthritis | Q187255 | ||
| P304 | page(s) | 1372-1378 | |
| P577 | publication date | 2004-03-05 | |
| P1433 | published in | Annals of the Rheumatic Diseases | Q4767876 |
| P1476 | title | Patient preferences for treatment of rheumatoid arthritis | |
| P478 | volume | 63 |
| Q36205494 | A Nationwide Survey on Patient's versus Physician´s Evaluation of Biological Therapy in Rheumatoid Arthritis in Relation to Disease Activity and Route of Administration: The Be-Raise Study |
| Q57168078 | A discrete choice experiment on preferences of patients with rheumatoid arthritis regarding disease-modifying antirheumatic drugs: the identification, refinement, and selection of attributes and levels |
| Q37427411 | A discrete choice experiment to explore patients' willingness to risk disease relapse from treatment withdrawal in psoriatic arthritis |
| Q37171323 | A pilot project examining the predicted preferences of patients and physicians in the primary prophylaxis of variceal hemorrhage |
| Q64057582 | A portfolio of biologic self-injection devices in rheumatology: how patient involvement in device design can improve treatment experience |
| Q50198473 | Adherence of rheumatoid arthritis patients to biologic disease-modifying antirheumatic drugs: a cross-sectional study. |
| Q37296221 | Being as Normal as Possible: How Young People Ages 16-25 Years Evaluate the Risks and Benefits of Treatment for Inflammatory Arthritis |
| Q36611201 | Benefit from preoperative radiotherapy in rectal cancer treatment: disease-free patients' and oncologists' preferences |
| Q38147723 | Clinical relevance of target identity and biology: implications for drug discovery and development |
| Q57330054 | Comparative effectiveness of treatment options after conventional DMARDs failure in rheumatoid arthritis |
| Q42666679 | Comparison of patient satisfaction with two different etanercept delivery systems. A randomised controlled study in patients with rheumatoid arthritis |
| Q27336043 | Complex antithrombotic therapy: determinants of patient preference and impact on medication adherence |
| Q36032715 | Decision tool to improve the quality of care in rheumatoid arthritis |
| Q38227517 | Discrete choice experiments in health economics: a review of the literature |
| Q38264743 | Economics of stratified medicine in rheumatoid arthritis |
| Q37446207 | Elderly patients' experiences using adaptive conjoint analysis software as a decision aid for osteoarthritis of the knee |
| Q92460630 | How Much Information and Participation Do Patients with Inflammatory Rheumatic Diseases Prefer in Interaction with Physicians? Results of a Participatory Research Project |
| Q47102973 | Identifying the primary outcome for a randomised controlled trial in rheumatoid arthritis: the role of a discrete choice experiment |
| Q36789973 | Impact of educational and patient decision aids on decisional conflict associated with total knee arthroplasty |
| Q34430218 | Impact of the Medicare Modernization Act of 2003 on utilization and spending for medicare part B-covered biologics in rheumatoid arthritis |
| Q45877225 | Individual patient monitoring in daily clinical practice: a critical evaluation of minimal important change. |
| Q37332615 | Methodologic evaluation of adaptive conjoint analysis to assess patient preferences: an application in oncology. |
| Q50951381 | Parents' preferences for drug treatments in juvenile idiopathic arthritis: a discrete choice experiment. |
| Q36868373 | Patient Preferences Regarding Rheumatoid Arthritis Therapies: A Conjoint Analysis |
| Q57117642 | Patient preferences among third agent HIV medications: a US and German perspective |
| Q37998124 | Patient preferences and healthcare outcomes: an ecological perspective |
| Q37473766 | Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy |
| Q80948577 | Patient preferences for sensory attributes of intranasal corticosteroids and willingness to adhere to prescribed therapy for allergic rhinitis: a conjoint analysis |
| Q35954580 | Patient preferences for treatment: report from a randomised comparison of treatment strategies in early rheumatoid arthritis (BeSt trial) |
| Q33928715 | Patient preferences in the treatment of diabetic retinopathy. |
| Q35112445 | Patient treatment preferences for osteoporosis |
| Q93152454 | Patient-Centered Approach to Develop the Patient's Preferences for Prostate Cancer Care (PreProCare) Tool |
| Q38887484 | Patients' and rheumatologists' preferences for the attributes of biological agents used in the treatment of rheumatic diseases in Spain |
| Q51233803 | Patients' willingness to trade off between the duration and frequency of rheumatoid arthritis treatments. |
| Q39214070 | Primary-care patients' trade-off preferences with regard to antidepressants. |
| Q41255645 | Psoriasis patients' willingness to accept side-effect risks for improved treatment efficacy. |
| Q40401339 | Quality of life and costs for different treatment strategies for rheumatoid arthritis |
| Q36973563 | Rheumatoid arthritis patients and rheumatologists approach the decision to escalate care differently: results of a maximum difference scaling experiment |
| Q64247809 | Shared Decision-Making and Patient Satisfaction in Japanese Rheumatoid Arthritis Patients: A New "Preference Fit" Framework for Treatment Assessment |
| Q35554857 | The design of a low literacy decision aid about rheumatoid arthritis medications developed in three languages for use during the clinical encounter |
| Q50916277 | The influence of patient perceptions of disease on medication intensification in daily practice. |
| Q37633537 | Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists |
| Q44196222 | Trade-off preferences regarding adjuvant endocrine therapy among women with estrogen receptor-positive breast cancer. |
| Q89536784 | Treatment Mode Preferences in Rheumatoid Arthritis: Moving Toward Shared Decision-Making |
| Q40593579 | Treatment preferences of patients with early rheumatoid arthritis: a discrete-choice experiment |
| Q37580905 | Tumour necrosis factor-alpha antagonists in the management of rheumatoid arthritis in the elderly: a review of their efficacy and safety |
| Q37000165 | Use of biologics in rheumatoid arthritis: current and emerging paradigms of care |
| Q89846223 | What Matters Most to Patients and Rheumatologists? A Discrete Choice Experiment in Rheumatoid Arthritis |
| Q33898674 | What is most important to patients when deciding about colorectal screening? |
| Q36469884 | When Patients Write the Guidelines: Patient Panel Recommendations for the Treatment of Rheumatoid Arthritis |
Search more.